Secondary Logo

Journal Logo

Basic Science

Early HIV-1 Diagnosis Using In-House Real-Time PCR Amplification on Dried Blood Spots for Infants in Remote and Resource-Limited Settings

Ngo-Giang-Huong, Nicole Pharm D, PhD*†‡; Khamduang, Woottichai MSc*†; Leurent, Baptiste MSc*†; Collins, Intira MSc*‡; Nantasen, Issaren BSc*†; Leechanachai, Pranee PhD; Sirirungsi, Wasna PhD; Limtrakul, Aram MD§; Leusaree, Tasana MD; Comeau, Anne Marie PhD; Lallemant, Marc MD*†‡; Jourdain, Gonzague MD, PhD*†‡

Author Information
JAIDS Journal of Acquired Immune Deficiency Syndromes: December 2008 - Volume 49 - Issue 5 - p 465-471
doi: 10.1097/QAI.0b013e31818e2531
  • Free



In 2007, there were an estimated 2.1 million children living with HIV, most of whom were infected through perinatal transmission.1 A World Health Organization (WHO) survey of 77 countries in the same year, among mostly lower middle-income countries, found that of the 715,000 infants born to HIV-infected women, only 8% (54,900) were tested within the first 2 months of life.1 In the absence of antiretroviral treatment, up to 40% of perinatally HIV-infected children in resource-limited countries may die before they reach the age of 1 year.2-4 Despite the scale up of antiretroviral therapy, children still account for a disproportionately high 16% of all HIV-related deaths when they represent only 7% of the HIV-infected population.1 This is partly reflective of their high risk of mortality in the first years of life and limited access to early HIV diagnosis. The WHO recommends that all HIV-infected infants, including those in resource-limited settings, initiate therapy in the first year of life due to high risk of mortality.5 However, in these settings, infants born to HIV-1-infected mothers have only access to antibody tests, which are widely available and low cost but only allow for a reliable diagnosis after 18 months of age when maternal antibodies have been cleared from the child's blood. Although this enables identification of the HIV-1-infected children who have survived the first 18 months of life for initiation of antiretroviral treatment, it fails to benefit to the infants at greatest risk, that is, those infants who develop severe immune deficiency early in their life. This highlights the urgent need for widely available and affordable access to early HIV-1 diagnosis in these settings.

Early diagnosis of HIV-1 infection requires the use of assays, which can detect HIV-1 virus or its components. Previously, this would require labor-intensive virus culture and highly secure laboratory facilities. To date, 2 techniques are currently used: the ultrasensitive detection of p24 antigen,6-12 that requires minimal laboratory equipment, and the polymerase chain reaction (PCR) for the amplification of HIV-1 RNA from plasma13-18 or DNA from mononuclear cells,13,15,17-21 which requires a standard molecular biology facility, allowing for positive diagnosis from as early as 1 day of age.

Among the PCR techniques currently used, the commercial qualitative Roche Amplicor HIV-1 DNA test has been widely considered as the gold standard test for early diagnosis of HIV-1 infection,19-21 especially because it has been refined to detect various HIV subtypes (Version 1.5).18,22-24 In Thailand where CRF01_AE is prevalent, Young et al18 found that, using cell pellets, its sensitivity increased from less than 40% at birth to 100% at 2 months of age, whereas its specificity was 100% regardless of the age of infant.

Since the early 1990s, the use of microsamples spotted on filter paper or dried blood spots (DBS) has been proposed to make state-of-the-art PCR techniques for the early HIV-1 diagnosis of infants accessible to rural and remote settings.23,25-35 Only 50 μL of blood are required per spot and the DBS can be safely and easily stored and shipped to a central laboratory using standard mail at room temperature.

For more than 10 years, early HIV-1 diagnosis using DBS and the Roche Amplicor HIV-1 DNA test (Version 1.5) has been widely used in studies on prevention of mother-to-child transmission (MTCT) of HIV in several research settings, in particular in the United States,20 Thailand,31,32 and South Africa.23 Although the results of these studies have translated into interventions for prevention of MTCT of HIV in the clinics, the early diagnosis technique utilized in the studies has not been widely transferred to these settings, partly due to its cost36 and the limitations of shipping liquid blood samples to molecular biology facilities. Indeed, there are safety, temperature, and time constraints for shipping liquid blood samples. Samples have to be appropriately packaged to prevent exposure to blood in case of leak or breakage; exposure to high ambient temperature during transportation may damage cells with the release of substances inhibiting PCR reaction; timely shipment at a cool temperature (2-10°C) is often not feasible on long distance in low-resource settings. The shipment of DBS samples bears none of these limitations.

By the end of the 1990s, a new technique, the real-time PCR technology was widely used in research laboratories for the detection of HIV-1 DNA. Assays based on real-time PCR display very high sensitivity and specificity, provide results more rapidly than classical PCR, and avoid crossover PCR contamination, thus do not require separated amplification and detection rooms. Moreover, equipment costs have dramatically reduced with increasing competition and improvement in detection system: standard Real-time machines, priced US $90,000 in 1995, are now priced from $20,000. With this increasing affordability, several groups developed real-time PCR assays to detect different gene regions of HIV-1, with the aim of expanding access to early diagnosis to resource-limited settings.37-42

In this article, we describe the performance of an in-house real-time PCR method versus the Roche Amplicor HIV-1 DNA test (Version 1.5), for the detection of HIV-1 DNA on DBS collected from infants born to HIV-1-infected mothers in Thailand. Also, as the Roche test had never been validated on DBS in this specific setting, we assessed its ability to detect HIV-1 CRF01_AE, the most prevalent strain in Thailand, using a HIV serology result at 18 months of age as the reference.


Origin of Samples

Comparison of In-House Real-Time PCR Test Versus the Roche Amplicor HIV-1 DNA Test (Version 1.5)

We used all DBS from non-breast-fed infants born to HIV-1-infected mothers collected (1) between July 2002 and November 2002 in the context of a perinatal HIV prevention trial study [Perinatal HIV Prevention Trial (Thailand) (PHPT)-2, NCT00398684],32 and (2) between September 2004 and September 2006 in the context of the pilot phase of a program to provide free access to early HIV-1 diagnosis in 31 public hospitals throughout Thailand.43

Validation of the Roche Test

We used all DBS from non-breast-fed infants born to HIV-1-infected mothers collected at their 4-month visit between January 1998 and July 2000 in the context of another perinatal HIV prevention trial study (PHPT-1, NCT00386230).31 These DBS were shipped at room temperature to the New England Newborn Screening Program (Boston, MA) laboratory for HIV-1 DNA PCR testing. For this analysis, we choose the 4-month samples as it has been shown that the Roche test can detect virtually all perinatal HIV-1 infections by this age in other epidemiological contexts23,29 and on liquid blood.18,23

The study was reviewed and approved by the Ethical Committee of the Faculty of Associated Medical Sciences, Chiang Mai University.

DBS Collection

Blood was collected on EDTA tubes then spotted onto a no. 903 filter paper (Schleicher & Schuell BioScience GmbH, Dassel, Germany), to fill at least 2 preprinted circles (approximately 50 μL of blood per spot). After drying for at least 4 hours in an air-conditioned room or overnight at room temperature, DBS were individually inserted in a gas-impermeable bag (Bitran bag; VWR, Buffalo Grove, IL) with a desiccant, and then stored at room temperature or −20°C until shipment to our laboratory in Chiang Mai, Thailand.

DNA Extraction

Genomic DNA was isolated from DBS by extraction with the polyvalent cationic resin, chelex 100 ((Biorad, Marnes-la-Coquette, Paris, France). Each spot was punched for 3 pieces with a quarter-inch hole puncher into a 2-mL screw-cap tube. After washing for 1 hour with a Triton X-100 Buffer (1X phosphate-buffered saline, 0.5% Triton X-100), 230 μL of 10% chelex solution was added and incubated at 100°C for 30 minutes. After centrifugation, 200 μL of DNA-containing chelex supernatant were then transferred into a new tube to be used directly for PCR amplification.

To ensure quality of testing, 1 blank filter paper spot was randomly placed every 15-20 samples in the sample set. As the cleaning of punchers with HCl can lead to rusting and may subsequently cause specimen-to-specimen contamination, the puncher was cleaned between specimens by punching a blank filter papers 6 times. This cleaning process was previously tested and validated at the New England Newborn Screening Program, Boston, MA (Dr. Comeau, PhD, Personal Communication 1996).

Amplification and Detection of Proviral HIV DNA Using the Roche Amplicor HIV-1 DNA Test (Version 1.5)

Fifty microliters of DNA-containing chelex supernatant were used for HIV-1 DNA amplification and detection using the commercial DNA PCR assay (Roche Amplicor HIV-1 DNA PCR test, Version 1.5; Roche Molecular Systems, Inc., Branchburg, NJ) according to the manufacturer's instructions.

Amplification and Detection of Proviral HIV-1 DNA Using In-House Real-Time PCR Assay

Amplification and detection of cellular HIV-1 DNA using in-house real-time PCR assay was performed as previously described by the Agence Nationale de Recherches sur le SIDA (AIDS) et les hépatites virales working group on HIV quantitation.37 The test is based on a 5′ nuclease assay in the long terminal repeat (LTR) gene using the ABI PRISM 7000 (Applied Biosystems, Foster City, CA). Briefly, 20 μL of DNA-containing chelex supernatant was amplified in duplicate with sense primer NEC 152 5′-GCCTCAATAAAGCTTGCCTTGA-3′ and reverse primer NEC 131 5′-TTTTAGAGATCGTCACCGCGG-3′ (Bioservice Unit, Bangkok, Thailand) in the presence of a labeled LTR probe 6FAM-CTGGTAACTAGAGATCCCT-MGB (Applied Biosystems, Warrington, Cheshire, United Kingdom) and Taqman Universal PCR master mix (Applied Biosystems, Foster City, CA). The probe was designed to be able to detect the 2 main subtypes circulating in Thailand, CRF01_AE and B, using sequences available in the Los Alamos sequence database.

All tests were performed independently from each other and blinded to clinical data.


HIV serology diagnosis was performed on site using either enzyme-linked immunosorbent assay or gelatin particle agglutination (GPA) test kits approved by the Ministry of Public Health of Thailand and according to WHO guidelines (1997-2001).44 Children with negative serology result at any age were considered HIV uninfected.

Statistical Analysis

To evaluate the performance of the in-house real-time PCR test, the Roche DNA PCR test was used as the reference. We calculated the concordance rate of positivity and negativity restricting the analysis to the first sample drawn in each infant and the 95% confidence intervals (CIs) using exact binomial distribution.

In the primary analysis, we determined the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the Roche Amplicor HIV-1 DNA test (Version 1.5) at the 4-month visit by using the HIV serology results at the 18-month visit as reference. Sensitivity and specificity were calculated as the percentage of children with a positive and negative Roche DNA PCR test among all children with a positive and negative HIV serology test at 18 months, respectively. The PPV and the NPV of the Roche DNA PCR test at 4 months were defined as the percentage of HIV-1-infected and HIV-1-uninfected children correctly diagnosed, respectively. The PPV and NPV were calculated for a MTCT rate of 3.9%, the overall rate reported by the national program in Thailand between 2001 and 200345 were as follows: [sensitivity × prevalence]/[sensitivity × prevalence + (1 − specificity) × (1 − prevalence)] and [specificity × (1 − prevalence)]/[specificity × (1 − prevalence) + (1 − sensitivity) × prevalence], respectively.46

In a secondary analysis, we also included the children with a 4-month visit DNA PCR result but no available serology result at the 18-month visit, assigning these cases a presumptive HIV status blindly to Roche DNA PCR results. Children were classified as HIV infected if a plasma viral load was above 10,000 copies per milliliter or 2 above 1000 copies per milliliter,5 or if clinical symptoms, anthropometric, or hematological data were presumptive of HIV infection5,47; otherwise they were classified as HIV uninfected.


Comparison Between the Roche Amplicor HIV-1 DNA Test (Version 1.5) and In-House HIV-1 Real-Time DNA PCR

One thousand three hundred nineteen DBS collected from 287 infants born in PHPT-2 and 645 infants enrolled in the pilot program were tested for HIV-1 DNA using the real-time PCR and Roche test. At the time of testing, the median age was 4.1 months (10th-90th percentiles: 1.7-7.2 months). The detection of HIV-1 by the 2 techniques was concordant in all 1319 DBS analyzed (Table 1). In the subset restricted to the first sample drawn in each of the 932 infants (median age: 3.5 months, 10th-90th percentiles: 1.5-6.7 months), the concordance rate was 100% (95% CI: 94.6% to 100%) for the 66 positive samples and 100% (95% CI: 99.6% to 100%) for the 866 negative samples. The earliest positive tests were obtained at birth.

Comparison of HIV DNA PCR Results of All DBS Tested With In-House Real-Time DNA PCR Test Versus Roche Test

Assessment of the Specificity and Sensitivity of the Roche Amplicor HIV-1 DNA Test, (Version 1.5) on DBS as Compared With HIV Serology at 18 months for the Diagnosis of HIV-1 Infection in Infants

Among the 1409 children born in the PHPT-1 trial, 1240 children had a blood sample available at the 4-month and 18-month visits, tested by Roche DNA PCR on DBS and HIV serology, respectively (Table 2).

Comparison of Roche HIV DNA PCR Versus HIV Serology Results

For the specificity and sensitivity analyses, 3 cases were excluded as follows: 1 HIV-1-infected infant with a negative serology result suspected to be related to severe immune deficiency (Table 3, case 1), and 2 infants with positive serology tests at 18 months but all negative virology tests until 6 months of age, suggesting late postnatal infections (cases 2 and 3).

History of HIV Testing for Children With Discordant DNA PCR and HIV Serology Results

Sensitivity of the Roche test was 98.6% (95% CI: 92.6% to 100.0%), and specificity was 99.7% (95% CI: 99.2% to 99.9%). Using the reported rate of HIV-1 transmission in Thailand (3.9%),45 the estimated PPV would be 94.0% and the NPV of 99.9%.

There were 4 discordant results. Three children tested Roche DNA PCR positive at 4 months of age but had a negative HIV serology at 18 months, and 1 child tested DNA PCR negative at 4 months of age with a positive HIV serology at 18 months. Table 3 summarizes the results of our investigations of these cases. Three discordant results were suspected to be due to human error: sample mislabeling (case 4) and laboratory error (cases 5 and 6). In the fourth case (case 7), 3 sequential HIV-1 DNA PCR-positive results were followed by 2 negative DNA PCR results and a negative serology diagnosis. If we excluded the 3 discordant cases due to human error, as they do not reflect an intrinsic lack of performance of the test, the sensitivity and specificity would be100% and 99.91%, respectively, with a PPV of 97.9% and NPV of 100%.

In the secondary analysis (see Methods), when we used the clinical, anthropometric, and hematological criteria to assign a presumptive infectious status to the 137 children with a 4-month DNA PCR result but no further HIV serology results, 18 were classified HIV infected and 119 HIV uninfected. All but 1 of the 4-month Roche DNA PCR results were concordant with the assumed HIV-1 status; the discordant case was DNA PCR negative at the 4-month visit (and at birth, 6 weeks, and 6-month visits) but was presumed HIV-1 infected because of failure to thrive, although with no infectious events. When including all 1374 children with a DNA PCR result at the 4-month visit, using the presumptive classification when serology was not available, the sensitivity of the Roche DNA PCR was 97.8% (95% CI: 92.3% to 99.7%) and specificity was 99.8% (95% CI: 99.3% to 100%). Using the rate of HIV-1 transmission in Thailand (3.9%), the estimated PPV would be 94.4% and the NPV 99.9%.

Cost of the Tests

We calculated that the cost per reportable test, including cost of filter papers, reagents, equipment maintenance, and human resources, was US $20 for the in-house assay and US $42 for the Roche Amplicor HIV-1 DNA test (Version 1.5).


This is the first report describing the use of an in-house real-time HIV-1 DNA PCR test on DBS for the early diagnosis of HIV-1 infection in a very large number of non-breast-fed infants born to HIV-1-infected mothers. The results using this test were identical to those obtained using the Roche DNA PCR on DBS.

Ideally, the specificity and sensitivity of the PCR-based HIV-1 diagnosis assays should be determined using a direct comparison with the HIV serology at 18 months. This was possible for the validation of the Roche Amplicor HIV-1 DNA test (Version 1.5), in the context of the PHPT-1 study, a clinical trial where children were not breast-fed and followed until 18 months of age or further until a serology confirmation test could be obtained. Although the Roche Amplicor HIV-1 DNA test (Version 1.5) has been widely validated and is the reference test for HIV-1 diagnosis in infants born to HIV-1-infected mothers, our concern was a theoretical lack of sensitivity due to the fact that we were dealing with subtype CRF01_AE. This concern was fully addressed as all positive serology tests at 18 months were also detected by the Roche Amplicor HIV-1 DNA test (Version 1.5).

This strategy could not be pursued for the validation of the in-house assay as the samples were either from children enrolled in the PHPT-2 study who were followed up to 12 months only, that is, before a reliable serology test could be done, or from children followed in the context of routine clinical care. Therefore we validated our new technique against the Roche Amplicor HIV-1 DNA test (Version 1.5), which has been validated in Thailand.

In our clinical studies, it was required that venous blood samples were collected in an EDTA tube for both safety laboratory tests and DBS preparation, therefore heel sticks were not used. In other settings, obtaining whole blood via heel stick would be easier. Several studies have shown that diagnosis of HIV infection using heel stick DBS is as reliable as venous blood draw.30,48,49 Our approach, using a LTR-specific probe to test DBS samples with an in-house real-time PCR assay, which is simpler and less prone to contamination than conventional PCR assays, is generalizable to other settings. Our probe was adapted to the B and CRF01_AE subtypes circulating in Thailand, which can be easily modified to fit other settings. The LTR region is one of the most conserved regions of HIV-1, and this is the reason why most of the real-time tests more recently developed39,50 are also using a LTR probe. For example, the Agence Nationale de Recherches sur le SIDA (ARNS) generic real-time reverse transcriptase-PCR assay used in France, Africa, and Cambodia was shown to be very reliable.50

It was important to verify that the use of DBS, which contains only 50 μL of blood, did not compromise the performance of the Roche DNA PCR assay. The sensitivity and specificity of the Roche assay on DBS at around 4 months of age, compared with HIV serology at around 18 months, were 98.6% and 99.7%, respectively. These values were not significantly modified when including the cases with no available serology results. These results are consistent with those reported by Young et al18 (sensitivity 100%; specificity 100%), using a larger quantity of blood (100 μL of whole blood) from 317 infants at 6 months of age in Thailand, and by Sherman et al23 with 98.8% sensitivity and 99.4% specificity of HIV-1 DNA PCR on DBS collected from 627 infants at 6 weeks of age in South Africa. Our results indicate a very high sensitivity of Roche HIV-1 DNA PCR on DBS when compared with the serology results.

Of the 4 discordant results between HIV-1 DNA PCR and serology, 3 were suspected to be due to human error (Table 3), emphasizing the importance of blood sample identification and labeling to ensure reliable diagnosis and the need for confirmation testing when important clinical decisions have to be taken on the basis of such results. Additionally, there was an HIV-1-infected child for whom HIV serology was negative at 18 and 24 months of age and the absence of detectable antibodies was suspected to be related to severe immune deficiency (Table 3). This further reinforces the benefit of HIV-1 DNA PCR for the diagnosis of HIV-1.

In summary, for more than 15 years, commercial tests such as the Roche DNA PCR test have been used in research settings for the diagnosis of HIV-1 infection in infants born to HIV-1-infected mothers. However, few countries have implemented this technique in their national antiretroviral programs. Even fewer countries are using DBS to facilitate remote access to early diagnosis of HIV-1 infection in infants.1,29,36,51 In 2005, fewer than 2% of infants had access to early PCR testing worldwide.52 For lower middle-income countries, such as Thailand, who rely predominantly upon domestic funding for the scale up of antiretroviral therapy, the cost of HIV-related services remains a significant issue. The use of low-cost in-house real-time HIV-1 DNA PCR test that can be used on DBS will facilitate access to early diagnosis of HIV-1 infection for all infants born to HIV-1-infected mothers, including those in rural and remote settings by transportation of samples by standard mail. Today, this is probably the easiest, most affordable, and reliable method ensuring that infected infants have timely access to the life saving antiretroviral therapy.


The following collaborators participated in the Perinatal HIV Prevention Trials (Thailand) and the pilot phase program for access to early HIV diagnosis: Bamrasnaradura: P. Tunthanathip, S. Sirikawin, and A. Chaovavanich; Banchang: S. Tragarngool, S. Chutimanukul, G. Kunawudhi, and N. Sangwannakul; Banglamung: J. Ithisukanan, K. Boonrod, S. Piyaman, P. Pinchan, S. Sirithadthamrong, and P. Jittiwattanapongs; Bhumibhol Adulyadej: S. Prommat, S. Nimkarn, S. Charnivises, V. Suraseranivong, P. Layangool, B. Gulakirt, K. Kengsakul, P. Prateeprat, and Y. Vonglertvit; Buddhachinaraj: P. Thanomrat, W. Wannapira, C. Chaipat, W. Ardong, P. Thanomrat, W. Boonyawatana, and N. Lertpienthum; Chachoengsao: A. Kanjanasing, C. Jirawison, R. Kwanchaipanich, R. Kaewsonthi, and V. Latdhivongsakorn; Chantaburi Prapokklao: S. Phongpanich, P. Yuthavisuthi, C. Ngampiyasakul, and S. Sooksengchai; D. Sinthuvanich; Chiang Dao: W. Saliddeechaikool; Chiang Kham: C. Putiyanun, S. Limsuwan, S. Charkrit, C. Mano, P. Jittamala, and C. Kulkolakan; Chiang Khong Royal Crown Prince: C. Taiyaitiang, S. Parinya, and S. Munjit; Chiang Rai Provincial: R. Hansudewechakul, J. Achalapong, R. Srismith, P. Wattanaporn (deceased), and S. Yanpaisan; Chonburi: N. Chotivanich, S. Hongsiriwon, P. Kittikoon, and C. Tantiyawarong; Doi Saket: P. Sirichithaporn; Hat Yai: S. Lamlertkittikul, B. Warachit, and K. Veerapradist; Health Promotion Center Region I: I. Tangtitawong, S. Sirinontakan, V. Japikanond, B. Ngamsiriudom, W. Laphikanont, and C. Kommongkol; Health Promotion Region 6 Khon Kaen: N. Winiyakul, S. Hanpinitsak, and W. Sinchai; Health Promotion Region 10 Chiang Mai: A. Limtrakul, W. Jitphiankha, S. Sethavanich, and V. Sittipiyasakul; Kalasin: B. Suwannachat, S. Srirojana, and S. Nitpanich; Khon Kaen: J. Ratanakosol, S. Tanupattarachai, M. Onchan, V. Jarupoonphol, and W. Chandrakachorn; Klaeng: S. Hotrawarikarn, S. Techapalokul, A. Palasudhi, and S. Sungpapan; Kranuan Crown Prince: R. Thongdej, T. Chaiyabut, P. Kovit, S. Benchakhanta, and A. Rattanaparinya; Lamphun: W. Matanasaravoot, R. Somsamai, W. Chavengchaiyong, P. Wannarit, K. Pagdi, C. Wannalit, and S. Yanpaisan; McCormick: C. Tangchaitrong, S. Suwansarakul, and C. Phimphilai; Mae Chan: S. Tantanarat, S. Piyaworawong, and S. Buranabanjasatean; Mae on: N. Pattanapornpun; Mae Sai: P. Jindaapilukkul, S. Kunkongkapan, T. Meephian, and K. Kongsing; Mahasarakam: S. Nakhapongse, S. Tonmat, K. Kovitanggoon, and W. Worngsatthanaphong; Nakhonpathom: S. Bunjongpak, V. Chalermpolprapa, and P. Hirunchote; Nakornping: V. Gomutbutra, P. Leelanitkul, K. Kunsuikmengrai, S. Kanjanavanit, S. Kahintapongs, and C. Sirinirundr; Nong Khai: N. P. Ruttana-Aroongorn, S. Potchalongsin, and T. Wichatrong; Nopparat Rajathanee: T. Chanpoo, S. Ruangsirinusorn, N. Thamanavat, P. Hotrarapavanond, S. Surawongsin, T. Chanpoo, and S. Santadusit; Phaholpolphayuhasena: Y. Srivarasat, P. Attavijtrakarn, and T. Buddhaboriwan; Phan: P. Lersruangpanya, S. Jungpichanvanich, T. Changchit, and S. Suwan; Phayamengrai: P. Tantiwattanakul, T. Onchomjum (deceased), and S. Kamsrisuk; Phayao Provincial: S. Bhakeecheep, J. Hemvuttiphan, S. Bhakeecheep, V. Lattiwongsakorn, S. Sangsawang, S. Techakulviroj, and S. Attawibool; Phranangklao: S. Mokkamakkul, S. Wanwaisart, S. Hongyok, S. Pipatnakulchai, and S. Watanayothin; Prajaksilapakom Army: D. Langkafa, S. Pratchayakul, and W. Srichandraphan; Ratchaburi: T. Chonladarat, N. Pinyotrakool, P. Malitong, O. Bamroongshawkasem, M. Jittwatanakorn, P. Bunjongjit, and S. Henpraserttae; Rayong: S. Lorenz Weerawatgoompa, V. Karnchanamayul, S. Ariyadej, P. Dumrongkitchaiporn, C. Pinyowittayakool, and C. Tantiyawarong; Roi-et: W. Atthakorn, P. Ananpatharachai, and W. Supanchaimat; Samutprakarn: P. Sabsanong, C. Sriwacharakarn, M. Hongsawinitkul, and A. Puangsombat; Samutsakorn: T. Sukhumanant, P. Thanasiri, and C. Pinsuwan; Sankhampang: N. Pipustanawong; Sanpatong: N. Akarathum; San Sai: W. Cowatcharagul; Somdej Pranangchao Sirikit: T. Hinjiranandana, S. Na Nakorn, W. Pornkitprasarn, and W. Rutirawat; Somdej Prapinklao: S. Suphanich, S. Maitrisathit, N. Tawornpanit, N. Kalawantavanich, P. Kanchanakitsakul, B. Tapawal, N. Kamolpakorn, P. Sunalai, and M. Nantarukchaikul; Srinagarind: P. Kosalaraksa, C. Sakondhavat, W. Laupattarakasem, and S. Kraitrakul; Institut de Recherche pour le Développement U174-Program for HIV Prevention and Treatment: S. Le Coeur, T.R Cressey, S. Chalermpantmetagul, T. Chitkawin, and S. Chailert; Faculty of Associated Medical Sciences, Chiang Mai University: N. Kongyai; (United States), University of Massachusetts: Gerstel-Thompson; Harvard School of public Health: K. Mac Intosh. We are indebted to Roche Molecular Systems for their support during the 2 perinatal HIV prevention trials, Perinatal HIV Prevention Trial (Thailand)-1, and Perinatal HIV Prevention Trial (Thailand)-2. We would like to thank M-L. Chaix-Baudier and C. Rouzioux, at Hopital Necker-Enfants, Malades, Paris, for their advice.


1. Towards Universal Access: Scaling up Priority HIV/AIDS Interventions in the Health Sector: Progress Report 2008. Geneva, Switzerland: World Health Organization; 2008.
2. Brahmbhatt H, Kigozi G, Wabwire-Mangen F, et al. Mortality in HIV-infected and uninfected children of HIV-infected and uninfected mothers in rural Uganda. J Acquir Immune Defic Syndr. 2006;41:504-508.
3. Newell ML, Coovadia H, Cortina-Borja M, et al. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet. 2004;364:1236-1243.
4. Violari A, Cotton M, Gibb D, et al. Antiretroviral therapy initiated before 12 weeks of age reduces early mortality in young HIV-infected infants: evidence from the Children with HIV Early Antiretroviral Therapy (CHER) Study. Presented at: 4th IAS Conference; July 22-25, 2007; Sydney, Australia.
5. Antiretroviral Therapy for HIV Infection in Infants and Children: Towards Universal Access. Recommendations for a Public Health Approach. Geneva, Switzerland: World Health Organization; 2006.
6. De Baets AJ, Edidi BS, Kasali MJ, et al. Pediatric human immunodeficiency virus screening in an African district hospital. Clin Diagn Lab Immunol. 2005;12:86-92.
7. Fiscus SA, Wiener J, Abrams EJ, et al. Ultrasensitive p24 antigen assay for diagnosis of perinatal human immunodeficiency virus type 1 infection. J Clin Microbiol. 2007;45:2274-2277.
8. Knuchel MC, Jullu B, Shah C, et al. Adaptation of the ultrasensitive HIV-1 p24 antigen assay to dried blood spot testing. J Acquir Immune Defic Syndr. 2007;44:247-253.
9. Patton JC, Sherman GG, Coovadia AH, et al. Ultrasensitive human immunodeficiency virus type 1 p24 antigen assay modified for use on dried whole-blood spots as a reliable, affordable test for infant diagnosis. Clin Vaccine Immunol. 2006;13:152-155.
10. Schupbach J, Boni J, Tomasik Z, et al. Sensitive detection and early prognostic significance of p24 antigen in heat-denatured plasma of human immunodeficiency virus type 1-infected infants. Swiss Neonatal HIV Study Group. J Infect Dis. 1994;170:318-324.
11. Sherman GG, Stevens G, Stevens WS. Affordable diagnosis of human immunodeficiency virus infection in infants by p24 antigen detection. Pediatr Infect Dis J. 2004;23:173-176.
12. Zijenah LS, Tobaiwa O, Rusakaniko S, et al. Signal-boosted qualitative ultrasensitive p24 antigen assay for diagnosis of subtype C HIV-1 infection in infants under the age of 2 years. J Acquir Immune Defic Syndr. 2005;39:391-394.
13. Cunningham CK, Charbonneau TT, Song K, et al. Comparison of human immunodeficiency virus 1 DNA polymerase chain reaction and qualitative and quantitative RNA polymerase chain reaction in human immunodeficiency virus 1-exposed infants. Pediatr Infect Dis J. 1999;18:30-35.
14. Delamare C, Burgard M, Mayaux MJ, et al. HIV-1 RNA detection in plasma for the diagnosis of infection in neonates. The French Pediatric HIV Infection Study Group. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;15:121-125.
15. Lambert JS, Harris DR, Stiehm ER, et al. Performance characteristics of HIV-1 culture and HIV-1 DNA and RNA amplification assays for early diagnosis of perinatal HIV-1 infection. J Acquir Immune Defic Syndr. 2003;34:512-519.
16. Nesheim S, Palumbo P, Sullivan K, et al. Quantitative RNA testing for diagnosis of HIV-infected infants. J Acquir Immune Defic Syndr. 2003;32:192-195.
17. Reisler RB, Thea DM, Pliner V, et al. Early detection of reverse transcriptase activity in plasma of neonates infected with HIV-1: a comparative analysis with RNA-based and DNA-based testing using polymerase chain reaction. J Acquir Immune Defic Syndr. 2001;26:93-102.
18. Young NL, Shaffer N, Chaowanachan T, et al. Early diagnosis of HIV-1-infected infants in Thailand using RNA and DNA PCR assays sensitive to non-B subtypes. J Acquir Immune Defic Syndr. 2000;24:401-407.
19. Barlow KL, Tosswill JH, Parry JV, et al. Performance of the Amplicor human immunodeficiency virus type 1 PCR and analysis of specimens with false-negative results. J Clin Microbiol. 1997;35:2846-2853.
20. Bremer JW, Lew JF, Cooper E, et al. Diagnosis of infection with human immunodeficiency virus type 1 by a DNA polymerase chain reaction assay among infants enrolled in the Women and Infants' Transmission Study. J Pediatr. 1996;129:198-207.
21. Kovacs A, Xu J, Rasheed S, et al. Comparison of a rapid nonisotopic polymerase chain reaction assay with four commonly used methods for the early diagnosis of human immunodeficiency virus type 1 infection in neonates and children. Pediatr Infect Dis J. 1995;14:948-954.
22. Lyamuya E, Olausson-Hansson E, Albert J, et al. Evaluation of a prototype Amplicor PCR assay for detection of human immunodeficiency virus type 1 DNA in blood samples from Tanzanian adults infected with HIV-1 subtypes A, C and D. J Clin Virol. 2000;17:57-63.
23. Sherman GG, Cooper PA, Coovadia AH, et al. Polymerase chain reaction for diagnosis of human immunodeficiency virus infection in infancy in low resource settings. Pediatr Infect Dis J. 2005;24:993-997.
24. Triques K, Coste J, Perret JL, et al. Efficiencies of four versions of the AMPLICOR HIV-1 MONITOR test for quantification of different subtypes of human immunodeficiency virus type 1. J Clin Microbiol. 1999;37:110-116.
25. Beck IA, Drennan KD, Melvin AJ, et al. Simple, sensitive, and specific detection of human immunodeficiency virus type 1 subtype B DNA in dried blood samples for diagnosis in infants in the field. J Clin Microbiol. 2001;39:29-33.
26. Cassol SA, Lapointe N, Salas T, et al. Diagnosis of vertical HIV-1 transmission using the polymerase chain reaction and dried blood spot specimens. J Acquir Immune Defic Syndr. 1992;5:113-119.
27. Comeau AM, Hsu HW, Schwerzler M, et al. Identifying human immunodeficiency virus infection at birth: application of polymerase chain reaction to Guthrie cards. J Pediatr. 1993;123:252-258.
28. Comeau AM, Pitt J, Hillyer GV, et al. Early detection of human immunodeficiency virus on dried blood spot specimens: sensitivity across serial specimens. Women and Infants Transmission Study Group. J Pediatr. 1996;129:111-118.
29. Creek T, Tanuri A, Smith M, et al. Early diagnosis of human immunodeficiency virus in infants using polymerase chain reaction on dried blood spots in Botswana's national program for prevention of mother-to-child transmission. Pediatr Infect Dis J. 2008;27:22-26.
30. Fischer A, Lejczak C, Lambert C, et al. Simple DNA extraction method for dried blood spots and comparison of two PCR assays for diagnosis of vertical human immunodeficiency virus type 1 transmission in Rwanda. J Clin Microbiol. 2004;42:16-20.
31. Lallemant M, Jourdain G, Le Coeur S, et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators. N Engl J Med. 2000;343:982-991.
32. Lallemant M, Jourdain G, Le Coeur S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med. 2004;351:217-228.
33. Panteleeff DD, John G, Nduati R, et al. Rapid method for screening dried blood samples on filter paper for human immunodeficiency virus type 1 DNA. J Clin Microbiol. 1999;37:350-353.
34. Sherman GG, Stevens G, Jones SA, et al. Dried blood spots improve access to HIV diagnosis and care for infants in low-resource settings. J Acquir Immune Defic Syndr. 2005;38:615-617.
35. Yourno J, Conroy J. A novel polymerase chain reaction method for detection of human immunodeficiency virus in dried blood spots on filter paper. J Clin Microbiol. 1992;30:2887-2892.
36. Creek TL, Sherman GG, Nkengasong J, et al. Infant human immunodeficiency virus diagnosis in resource-limited settings: issues, technologies, and country experiences. Am J Obstet Gynecol. 2007;197(Suppl 3):S64-S71.
37. Burgard M, Chaix ML, Ngo N, Leruez M, Rouzioux C, and the ANRS group on HIV-1 Quantification and the French Perinatal HIV infection study group. Real-Time HIV-1 PCR for the diagnosis of infection in newborns of African mother. Paper presented at: 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago, IL.
38. Desire N, Dehee A, Schneider V, et al. Quantification of human immunodeficiency virus type 1 proviral load by a TaqMan real-time PCR assay. J Clin Microbiol. 2001;39:1303-1310.
39. Drosten C, Panning M, Drexler JF, et al. Ultrasensitive monitoring of HIV-1 viral load by a low-cost real-time reverse transcription-PCR assay with internal control for the 5′ long terminal repeat domain. Clin Chem. 2006;52:1258-1266.
40. Luo W, Yang H, Rathbun K, et al. Detection of human immunodeficiency virus type 1 DNA in dried blood spots by a duplex real-time PCR assay. J Clin Microbiol. 2005;43:1851-1857.
41. Ou CY, Yang H, Balinandi S, et al. Identification of HIV-1 infected infants and young children using real-time RT PCR and dried blood spots from Uganda and Cameroon. J Virol Methods. 2007;144:109-114.
42. Rouet F, Ekouevi DK, Chaix ML, et al. Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting. J Clin Microbiol. 2005;43:2709-2717.
43. Collins I, Ngo-Giang-Huong N, Leechanachai P, et al. Expanding access to early HIV diagnosis for infants in Thailand: from technology transfer to community outreach. AIDS 2006. Presented at: XVI International AIDS Conference; August 13-18, 2006; Toronto, Canada.
44. Ministry of Public Health. National Guidelines for the Clinical Management of HIV Infection in Children and Adults. 6th ed. Nonthaburi, Thailand: Ministry of Public Health, Thailand; 2000.
45. Plipat T, Naiwatanakul T, Rattanasuporn N, et al. Reduction in mother-to-child transmission of HIV in Thailand, 2001-2003: results from population-based surveillance in six provinces. AIDS. 2007;21:145-151.
46. Pepe MS. The Statistical Evaluation of Medical Tests for Classification and Prediction. Oxford, England: Oxford University Press; 2003.
47. WHO. WHO Case Definitions of HIV for Surveillance and Revised Clinical Staging and Immunological Classification of HIV-Related Disease in Adults and Children. Geneva, Switzerland: World Health Organization; 2007.
48. Nyambi PN, Fransen K, De Beenhouwer H, et al. Detection of human immunodeficiency virus type 1 (HIV-1) in heel prick blood on filter paper from children born to HIV-1-seropositive mothers. J Clin Microbiol. 1994;32:2858-2860.
49. Patton JC, Akkers E, Coovadia AH, et al. Evaluation of dried whole blood spots obtained by heel or finger stick as an alternative to venous blood for diagnosis of human immunodeficiency virus type 1 infection in vertically exposed infants in the routine diagnostic laboratory. Clin Vaccine Immunol. 2007;14:201-203.
50. Rouet F, Chaix ML, Nerrienet E, et al. Impact of HIV-1 genetic diversity on plasma HIV-1 RNA Quantification: usefulness of the Agence Nationale de Recherches sur le SIDA second-generation long terminal repeat-based real-time reverse transcriptase polymerase chain reaction test. J Acquir Immune Defic Syndr. 2007;45:380-388.
51. Cherutich P, Inwani I, Nduati R, et al. Optimizing paediatric HIV care in Kenya: challenges in early infant diagnosis. Bull World Health Organ. 2008;86:155-160.
52. Luo C, Akwara P, Ngongo N, et al. Global progress in PMTCT and paediatric HIV care and treatment in low- and middle-income countries in 2004-2005. Reprod Health Matters. 2007;15:179-189.

access to treatment; dried blood spots; early diagnosis; HIV-1 real-time DNA PCR; infant; remote and resource-limited settings

© 2008 Lippincott Williams & Wilkins, Inc.